RxDoctor Payments DataLook up a doctor →

Chheany Ung, MD

Pain Medicine · Roanoke, VANPI 1356469522

Payments from drug & device makers

$624,276in general payments, 2019–2025

Across 1,320 payments — averaging $472.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nalu Medical, Inc.$380K
  • Nevro Corp.$187K
  • Globus Medical$19K
  • Abbott$15K
  • Medtronic$5K
  • Saluda Medical Americas, Inc.$4K
  • plus $15K from 37 others
$2,516in research payments, 2019–2025

Across 2 payments — averaging $1258.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nevro Corp.$3K
  • Saluda Medical Americas, Inc.$16

What the payments were for

  • Consulting fees$51,06726%
  • Speaking & faculty fees$72,24436%
  • Travel & lodging$23,20712%
  • Food & beverage$50,82526%
  • Entertainment$8850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624,276 in reported general payments places this provider in the 95th percentile of 150 pain medicine providers in Virginia.

See all pain medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$1,560,098
Medicare patients
1,338
Services billed
109,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina11$14,103
Buprenorphine13$3,450
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen67$1,304
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen27$727
Gabapentin51$562
Tramadol Hcl60$444
Pregabalin25$415
Oxycodone Hcl27$371
Tizanidine Hcl16$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$336$14,10311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 pain medicine providers in Virginia.

Other pain medicine in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →